Arecor Therapeutics (STU:6UI) Cash Payments

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:6UI Arecor Therapeutics PLC STU:6UI
39 GF Score
Price €0.69
GF Value €0.49
! 6 Warning Signs
View Full Analysis

What is Arecor Therapeutics Cash Payments?

Cash Payments only applicable to companies reporting Cash Flow from Operations in direct method.

STU:6UI
39GF Score
Arecor Therapeutics PLC STU:6UI
Cash Payments is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arecor Therapeutics (STU:6UI) Overvalued in 2026?

Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued. The current stock price of €0.69 is trading 39.8% above its estimated GF Value™ of €0.49.

Key valuation signals for STU:6UI:

  • Cash Payments:
  • GF Value™: €0.49 vs. price of €0.69 (39.8% above fair value)
  • GF Score™: 39/100 with 6 warning signs

No single metric tells the full story. See the STU:6UI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Arecor Therapeutics Business Description

Other Exchanges AREC:UK
Address Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
39GF Score

Get the complete analysis for STU:6UI

Cash Payments is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.69
Price
€0.49
GF Value